Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) are starting to transform the treatment for patients with advanced cancer. The extensive application of these antibodies for various cancer obtains exciting anti-tumor immune response by activating T cells. Although the encouraging clinical benefit in patients rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Aohan, Hou, Kaiyu, Huang, Qiubo, Lei, Yujie, Chen, Wanling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249937/
https://www.ncbi.nlm.nih.gov/pubmed/32508809
http://dx.doi.org/10.3389/fimmu.2020.00783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249937/
https://www.ncbi.nlm.nih.gov/pubmed/32508809
http://dx.doi.org/10.3389/fimmu.2020.00783

Ejemplares similares